Related Experiment Videos
Hemolytic anemia in patients receiving sulfasalazine
Digestion
|January 1, 1978
Summary
Sulfasalazine can cause hemolytic anemia in patients with inflammatory bowel disease. This study found 43% of patients showed signs of hemolysis, often without Heinz body formation, linking it to sulfapyridine levels.
Area of Science:
- Gastroenterology
- Hematology
- Pharmacology
Background:
- Sulfasalazine is a common treatment for inflammatory bowel disease (IBD).
- Hemolytic anemia is a known, but not fully understood, complication of sulfasalazine therapy.
Purpose of the Study:
- To investigate the incidence and characteristics of sulfasalazine-induced hemolysis in IBD patients.
- To explore the relationship between hemolysis, Heinz body formation, and sulfasalazine metabolite levels.
Main Methods:
- Starch gel electrophoresis was used to detect hemolysis in 40 IBD patients on sulfasalazine.
- Hemoglobin levels, reticulocyte counts, and Heinz body presence were assessed.
- Serum levels of sulfasalazine and its metabolite sulfapyridine were measured.
Main Results:
- 43% of patients (17/40) exhibited evidence of hemolysis.
- Only 47% of patients with hemolysis showed Heinz body formation.
- Hemolysis correlated significantly with serum sulfapyridine levels, not sulfasalazine levels.
- Reduced hemoglobin and elevated reticulocyte counts were observed in patients with hemolysis.
Conclusions:
- Sulfasalazine-induced hemolysis is a frequent complication in IBD patients.
- Heinz body formation is not a universal indicator of sulfasalazine-induced hemolysis.
- Serum sulfapyridine levels appear to be more closely associated with hemolysis than sulfasalazine levels.